To explore the efficacy and safety of L-asparaginase in newly-diagnosed extranodal nature killer (NK)/T –cell lymphoma (ENKTL), we conducted a prospective phase II study of L-asparaginase, cyclophosphamide, vincristine, doxorubicin and dexamethasone (CHOP-L) regimen in combination with radiotherapy.
Patients and methods
Patients with newly diagnosed ENKTL and an ECOG performance status of 0 to 2 were eligible for enrollment. Treatment included 6–8 cycles of CHOP-L (cyclophosphamide, 750 mg/m2 day 1; vincristine, 1.4 mg/m2 day 1 (maximal dose 2 mg), doxorubicin 50 mg/m2 day 1; dexamethasone 10 mg days 1–8; L-asparaginase 6000 u/m2 days 2–8). Radiotherapy was scheduled after 4–6 cycles of CHOP-L regimen, depending on stage and primary anatomic site. The primary endpoint was complete response (CR) rate.
A total of 38 eligible patients were enrolled. The median age was 40.5 years (range, 15 to 71 years). Their clinical characteristics were male to female ratio, 24:14; Ann Arbor stage I, 20; II, 11; III, 3; IV, 4. CR and overall response rates were 81.6% (95% CI, 69.3% to 93.9%) and 84.2%, respectively. With a median follow-up of 25 months, the 2-year overall survival, progression-free survival and disease-free survival rates were 80.1% (95%CI, 73.3% to 86.9%), 81% (95%CI, 74.5% to 87.5%) and 93.6% (95%CI, 89.3% to 97.9%), respectively. The major adverse events were myelosuppression, liver dysfunction, and digestive tract toxicities. Grade 3 to 4 leukopenia and neutropenia were 76.3% and 84.2%, respectively. No treatment-related death was observed.
CHOP-L chemotherapy in combination with radiotherapy is a safe and highly effective treatment for newly diagnosed ENKTL.
Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a highly aggressive and heterogeneous disease. It is much more prevalent in Asia than in Western countries. Its frequency among all malignant lymphoma is around 3%-10% in East Asia, but <1% in western countries[1, 2]. Unlike that in Western countries, ENKTL is the most common peripheral T-cell lymphoma in China, with rate as high as 11% of all lymphoma[3, 4]. Even though two-thirds of ENKTL patients present with localized disease, prognosis remains dismal. Due to its rarity, it is difficult to do randomized, controlled trial. Therefore the best first-line chemotherapy regimen is not yet established.
Although radiation plays an important role in localized disease, treatment failure (including distant and loco-regional relapse) still occurs in nearly 50% of patients who are treated by radiation alone, and the 5-year survival rate ranges from 29.8% to 66%[6–9].
ENKTL tends to be resistant to conventional chemotherapy. Thus, it is imperative to develop an effective chemotherapy regimen. L-asparaginase, which is not regulated by multidrug resistance (MDR) gene, has been reported in relapsed or refractory ENKTL in retrospective studies with good response and survival rate[10–13]. Yong et al. first attempted to use L-asparaginase in refractory or relapsed ENKTL in 1990 in our center. Subsequently a series of studies from our center[10, 15–17] and two prospective studies[18, 19] confirmed the remarkable efficacy of L-asparaginase in both newly- diagnosed stage IV and refractory/ relapsed ENKTL. These data suggested that L-asparaginase- based regimens represented a reasonable option in advanced, relapsed or refractory ENKTL[20, 21].
To explore the value of L-asparaginase for newly diagnosed ENKTL, we conducted this prospective phase II study of L-asparaginase- based regimen in combination with radiotherapy. Based on our previous studies[10, 16, 17], we selected to combine L-asparaginase with cyclophosphamide, vincristine, doxorubicin and dexamethasone (CHOP-L). The design of the CHOP-L regimen was based on several considerations. Although some ENKTL showed resistance to CHOP regimen, 27% of patients still acquired CR from CHOP regimen. Dexamethasone was used instead of prednisone to better prevent the adverse reactions of L-asparaginase.
Patients and methods
Patients of more than 14 years old with newly diagnosed ENKTL were eligible for CHOP-L phase II study, irrespective of stage and primary anatomic site. Eligibility criteria included biopsy- proven diagnosis of ENKTL, according to the World Health Organization (WHO) classification. Tumor cells had a cytoplasmic CD3+, CD20- phenotype, a cytotoxic profile and evidence of EBV infection (EBV- encoded small nuclear RNA by in situ hybridization). Most cases (35 among 38 with this marker available) were CD56+. The pathological diagnosis of all cases was confirmed by hematopathologists from our institution. Patients must have no prior chemotherapy or radiotherapy, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life expectancy of more than 3 months. Patients also had to have adequate bone marrow function (i.e., hemoglobin ≥80 g/l, absolute neutrophil count ≥ 1.0 × 109/L, platelets ≥ 100 × 109/L), renal function (i.e., serum creatinine ≤177 μmol/L),hepatic function (i.e., total bilirubin ≤ two times the upper limit of normal, and ALT /AST ≤2.5 times the upper limit of normal).
The exclusion criteria included CNS involvement, other concomitant malignant tumor, severe infection, pregnancy or breastfeeding, or psychiatric disorders. Patients were also excluded if they had a cardiac contraindication to doxorubicin therapy (e.g., abnormal contractility on echocardiography) or a neurologic contraindication to vincristine (e.g., peripheral neuropathy).
All patients gave their written informed consent before entering the study, which has been approved by the independent ethics committee of our institution.
Study design and treatment
This is an open-label, single-arm prospective phase II study. The patients received 6–8 cycles of L-asparaginase, cyclophosphamide, vincristine, doxorubicin and dexamethasone (CHOP-L) given every 3 weeks. The dosage and administration schedule of CHOP-L were as follows: cyclophosphamide, 750 mg/m2 intravenously on day 1; vincristine, 1.4 mg/m2 intravenously on day 1 (maximal dose 2 mg); doxorubicin 50 mg/m2 intravenously on day 1; dexamethasone 10 mg intravenously on days 1–8; Escherichia coli L-asparaginase (Leunase, Kyowa Hakko Kogyo Co., Ltd, Tokyo, Japan; Changzhou Qianhong Bio-pharma Co., Ltd, Jiangsu, China) 6000 u/m2 intravenously on days 2–8.
Intradermal test was required prior to the administration of L-asparaginase. If intradermal test was positive or allergic reaction to L-asparaginase was observed, L-asparaginase was replaced by polyethylene glycosylated (PEG) - asparaginase (pegaspargase, Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) 2500 u/m2 intramuscularly on day 2. During the treatment, patients were routinely monitored for coagulation function (including fibrinogen). Granulocyte colony- stimulation factor (G-CSF) was initiated when WBC count decreased to less than 2.0 × 109/L or absolute neutrophil count ≤1.0 × 109/L. G-CSF was discontinued when WBC count exceeded 10 × 109/L or absolute neutrophil count ≥5.0 × 109/L.
For upper aerodigestive tract NK/T lymphoma, patients with Ann Arbor stage I and II disease received involved- field radiation (IFRT) after 4–6 cycles CHOP-L regimen, and then finished remaining chemotherapy after completion of radiation; patients with Ann Arbor stage III and IV disease received IFRT for the primary anatomic site or residue lesion after finishing all chemotherapy. The time point of radiation was made at the discretion of treating physician. Three-dimensional conformal radiotherapy was done by using 6 MV photons generated from a linear accelerator at 2.0 Gy per daily fraction over 4–6 weeks.
Baseline evaluation was performed within 2 weeks before enrollment. This consisted of a history taking, physical examination, routine blood tests including serum biochemistry with lactate dehydrogenase (LDH), bone marrow aspiration and biopsy, and lumber puncture. Computed tomography (CT), magnetic resonance imaging, and whole-body PET-CT scan with diagnostic quality CT, when possible, were used to evaluate stage, to assess the efficacy every 2 cycles, at the end of the study treatment, and to monitor relapse.
ENKTL was divided into two subtypes: upper aerodigestive tract NK/T- cell lymphoma (UNKTL) and extra- upper aerodigestive tract NK/T- cell lymphoma (EUNKTL). These two subtypes were defined in previous studies[24, 25]. Lesion extending to adjacent organs/tissues was defined as Ann Arbor stage IE.
The primary endpoint was complete response (CR) rate. Secondary endpoints were overall response rate (RR), overall survival (OS), progression- free survival (PFS), disease- free survival (DFS) and toxicity.
Tumor responses were assessed every two cycles of chemotherapy, and were classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) according to the Revised Response Criteria for Lymphoma. The interim assessment was made 2 weeks after the fourth cycle of the CHOP-L protocol, and the final assessment was made one month after the end of treatment.
All adverse reactions were graded each cycle according to the National Cancer Institute Common Toxicity Criteria, version 3.
In our center, CR rate was 27% after CHOP regimen plus radiation for previously untreated ENKTL patients, and 55.6% with L-asparaginase, dexamethasone, plus vincristine for relapsed or refractory patients. Therefore, a target CR rate of 56% with CHOP-L regimen was used to calculate the sample size. With a statistical power of 80% and a one-sided, type I error of 5%, the number of eligible patients required for this study was calculated to be 34. With an estimated dropout rate at 10%, the total sample size needed was 38 patients.
OS was defined as the time from diagnosis to death from any cause or the date of last follow-up. PFS was measured from diagnosis to first progression, relapse after response, or death from any cause, or the date of last follow-up. DFS was calculated as the time from CR to death from any cause, relapse, or the date of last follow-up.
Data were analyzed using SPSS Statistics 16.0 software. OS, PFS and DFS were estimated using the Kaplan-Meier method. Survival curves were compared between groups using log-rank test. The impact of different factors on response was evaluated by chi-square test. P value less than 0.05 was considered statistically significant.
Between November 2008 and July 2012, a total of 38 Chinese patients (Mongoloid) were enrolled in this prospective study. Histologic diagnosis of all patients was confirmed as ENKTL by our central pathology review. The clinical characteristics of all patients are summarized in Table 1. Eighteen (47.4%) patients came from North China, 8 (21.1%) from the East coast region, 6 (15.8%) from Northeast China, 5 (13.2%) from Central China, and 1 (2.6%) from Southwest China.
Clinical characteristics of patients with newly diagnosed ENKTL
There was a slight male predominance, with a male-to-female ratio of 1.7: 1. The median age was 40.5 years (range, 15–71 years), and 36 patients (94.7%) were less than 60 years old. The most frequent presenting symptoms were nasal obstruction (28/38, 73.7%),nasal mass (10/38, 26.3%),fever (5/38, 13.2%), pharyngalgia (4/38, 10.52%). The median time to diagnosis was 6 months (range, 1–48 months). 22 patients (57.9%) had B symptoms at presentation. Thirty six patients (94.7%) had upper aerodigestive tract NK/T-cell lymphoma (UNKTL), and only 2 were extra- upper aerodigestive tract NK/T-cell lymphoma (EUNKTL). Primary anatomic sites were naval cavity (n = 29), nasopharynx (n = 3), oropharynx (n = 4), coeliac lymph node (n = 1), and intestinal tract (n = 1). None of the patients had CNS or bone marrow involvement. 81.6% of the patients (31/38) had localized disease (Ann Arbor stage I/II). Among the 20 UNKTL patients with Ann Arbor stage I, 14 (70%) had contiguous extension to the adjacent organs/tissues (i.e., paranasal sinus, Waldeyer’s ring, bone, skin). HBs-Ag was negative in all patients, and anti-HBc Ab was positive in 11 patients. Platelets count and serum albumin level were normal in all patients.
All the patients received the scheduled treatment. The total cycles of CHOP-L regimen received by all patients were 193, with a median of 5 cycles (range, 2–8 cycles). Seven patients who rapidly progressed only received 2–4 cycles of CHOP-L. Because of positive intradermal test or allergic reaction related to L-asparaginase, 11 patients (28.9%) used pegaspargase instead of L-asparaginase in a total of 28 cycles, which accounted for 14.5% of all CHOP-L cycles, and the median cycle was 2 (range, 1–5 cycles).
In the 36 UNKTL patients, 31 received radical radiotherapy (RT). Two patients acquired CR after 4 or 8 cycles of CHOP-L regimen, and then rejected RT in fear of its toxicity. Three patients had no chance to receive RT due to rapid progression. The median radiation dose was 52 Gy (range, 40-60 Gy), and only two patients’ dosage was less than 50 Gy. 14 patients received RT after the end of chemotherapy (CT), and the other 17 patients received sandwich-like chemoradiotherapy (i.e., they received RT following 4 cycles of CHOP-L protocols, and then finished the remaining CHOP-L).
The efficacy was estimated in all the 38 patients who received the scheduled treatment. After 4 cycles of CHOP-L regimen, interim assessment showed that there were 27 patients with CR (71.5%), 7 with PR (18.4%), 1 with SD (2.6%), and 3 with PD (7.9%). At the completion of all the chemoradiotherapy, 25 remained in CR, and 6 patients with PR converted to CR (Figure 1). Therefore 81.6% (31/38) of the patients achieved CR, with one PR (2.6%), and six PD (15.8%) after CHOP-L in combination with RT. The overall response rate (ORR) was 84.2%.
Among all the clinical factors, several had significant effects on CR status (p<0.05), specifically Ann Arbor stage (p =0.026) , B symptoms (p =0.014), ECOG score (p =0.013), IPI (p =0.001), NK/T-cell PI(p =0.001), LDH (p =0.013), WBC (p =0.004). Others factors, including age, gender, regional lymph node involvement, adjacent organ/tissue involvement in UNKTL, ESR, β2- microglobulin, hemoglobin and pegaspargase usage did not have significant effect on CR rate (Table 2).
Clinical characteristics and response rate after CHOP-L regimen plus radiation
Ann Arbor Stage
Tumor extending to adjacent organ/tissue in UNKTL
Region LN involvement
Bony invasion or perforation
ECOG performance status
NK/T-cell PI score
Serum LDH level
White blood cell count
<4.0 × 109/L
≥4.0 × 109/L
Pegaspargase replacement of L-asparaginase
All of the 38 patients were eligible for survival analysis. The median follow-up for all patients was 25 months (range, 4–50 months). The median OS, DFS, and PFS points have not been reached. The 2-year OS, PFS and DFS rates were 80.1% (95%CI, 73.3% to 86.9%), 81% (95%CI, 74.5% to 87.5%) and 93.6% (95%CI, 89.3% to 97.9%), respectively (Figure 2).
During the follow-up period, seven patients died due to disease progression. Patients who achieved CR after treatment remained in CR to date, including the two UNKTL patients who declined radiation. One 38 year- old male patient with stage IIB at presentation achieved PR after treatment, and then received autologous hematopoietic stem cell transplantation (auto- HSCT). But six months later, the tumor progressed. This patient failed salvage chemotherapy and died of disease progression. His survival was 20 months. Another 27 year-old male with Ann Arbor stage IVB had primary refractory disease after 4 cycles of CHOP-L. He also died of systemic disease progression. Other five patients also had PD after 2–4 cycles of CHOP-L. They all died of lymphoma- associated hemophagocytic syndrome (HPS).
In univariate analysis, the following clinical factors were significant poor prognostic factors for OS and PFS (p <0.05): Ann Arbor stage, B symptoms, ECOG score, IPI score, NK/T-cell PI score, LDH (>240 IU/L), leukopenia (<4.0 × 109/L) and CR status. However, these factors except leukopenia were not significant for DFS. Other factors, including gender, tumor extending to adjacent organ/tissue in UNKTL, regional lymph node involvement, bony invasion or perforation, ESR >30 mm/hr, β2- microglobulin, hemoglobin<110 g/L and pegaspargase replacement of L-asparaginase had no significant effects on OS or PFS (Table 3).
Univariate analysis of prognostic factors
Ann Arbor Stage
Tumor extending to adjacent organ/tissue in UNKTL
Regional LN involvement
Bony invasion or perforation
ECOG performance status
NK/T-cell PI score
LDH >240 IU/L
ESR >30 mm/hr
β2- microglobulin elevated
Hemoglobin <110 g/L
Leukopenia (<4.0 × 109/L)
CR after treatment
Note. The data with “bold fonts” emphasized that the P values were less than 0.05.
The major adverse reactions to CHOP-L regimen were myelosuppression, liver dysfunction, coagulation dysfunction (decrease in fibrinogen) and digestive tract toxicities (Table 4). Grade 3 to 4 leukopenia and neutropenia were frequent (76.3% and 84.2%, respectively). Anemia and thrombocytopenia were mostly grade 1 to 2. Most patients (33/38, 86.8%) had a decrease in fibrinogen after L-asparaginase, but no increase in hemorrhage occurred. Other noticeable toxicities included hyperlipidemia, hypocalcemia, hypoglycemia and hyperglycemia (Table 4).
Toxicity profile of CHOP-L regimen
Toxicity Incidence, No. (%)
Digestive tract effect
Increase in ALT/AST
Increase in bilirubin
Increase in BUN
16(42.1%), the minimum value was 27.9 g/L
Decrease in FIB
33(86.8%), the minimum value was 55.2 mg/dL
8(21.1%), the maximum value was 16.04 mmol/L
9(23.7%), the maximum value was 11.31 mmol/L
5(13.2%), the minimum value was 1.11 mmol/L
Changes in EKG
5(13.2%), 3 with grade 1, 2 with grade 2
Infection with grade 3 to 4 neutropenia
Infection without neutropenia
Abbreviations: BUN blood urea nitrogen, FIB fibrinogen.
Nine patients (23.7%) had EKG abnormalities, including sinus tachycardia in six patients. The EKG changes had no effect on cardiac function or on chemotherapy schedules. Five patients (13.2%) had interstitial pneumonia, all recovered after corticosteroid treatment. Eight patients (21.1%) developed febrile neutropenia. One patient had allergic reaction to L-asparaginase infusion, and ten patients experienced a positive intradermal test after a median of 2 cycles of L-asparaginase (range, 1–5 cycles). No pancreatitis was seen. No treatment- related mortality was observed.
This study applied frontline treatment with L-asparaginase- based chemotherapy for ENKTL. Thirty- eight patients were recruited in this study. We excluded several types of patients with CNS involvement, other concomitant malignant tumor, severe infection, pregnancy or breastfeeding, or psychiatric disorders, because those situations would affect the proceeding of CHOP-L chemotherapy. This study indicated that the efficacy of L-asparaginase- based regimen (CHOP-L) in combination with radiotherapy was excellent for newly-diagnosed ENKTL. At the completion of treatment, the CR rate was 81.6%, which far exceeded the targeted CR rate of 56%. When we divided 36 upper aerodigestive tract NK/T- cell lymphoma (UNKTL) patients into localized group (Ann Arbor stage I/II) and advanced group (Ann Arbor stage III/IV), we found that CR rate was 90% and 50% in these two groups, respectively. The 2-yr OS and 2-yr PFS were 88.3%% and 89.5% in localized group, 50% and 50% in advanced group, respectively. Even though 18.4% of the cases recruited in our study were at Ann Arbor stage III/IV, the CR rate and survival were similar or superior to those reported from two concurrent chemo-radiotherapy studies (CCRT) for localized disease[28, 29] (Table 5), and much better than historical data using anthracycline- based chemotherapy plus radiotherapy[15, 30, 31]. The CR rate for those ENKTL patients at advanced stage in our study was 42.9% (3/7), similar to those treated with SMILE regimen.
Study comparison with recent prospective studies of ENKTL
Author, year, country
No. of patients
RT (Gy) Med. (Ran.)
Lin et al. 2013, China (this study)
Total cohort: 38
CHOP-L ± RT
80.1% (2 yr-)
81% (2 yr-)
stage I/II: 30
stage III/IV: 6
Kim et al. 2009, Korea
Newly- diagnosed, stage I/II, UNKTL
CCRT + VIPD
86.3% (3 yr-)
85.2% (3 yr-)
Yamaguchi et al. 2009, Japan
Newly- diagnosed, stage I/II, UNKTL
CCRT + DeVIC
50: stage I, 50.4: stage II
78% (2 yr-)
67% (2 yr-)
Jaccard et al. 2011, France
Median OS: 12.2 months
Yamaguchi et al. 2011 Japan
Newly- diagnosed stage IV, Refractory, relapsed
55% (1 yr-)
53% (1 yr-)
Abbreviations: No. number, RT radiotherapy, Med Median; Ran, Range, CR complete remission, OS, overall survival, PFS progression-free survival, yr year, UNKTL Upper aerodigestive tract NK/T- cell lymphoma, CCRT concurrent chemoradiotherapy, CHOP-L cyclophosphamide, vincristine, doxorubicin, dexamethasone, and L-asparaginase, VIPD etoposide, ifosfamide, cisplatin, and dexamethasone, DeVIC dexamethasone, etoposide, ifosfamide, and carboplatin, AspaMetDex, L-asparaginase, methotrexate, and dexamethasone, SMILE methotrexate, ifosfamide, dexamethasone, etoposide, and L-asparaginase.
In our previous work, ENKTL patients treated with CHOP regimen followed by IFRT had a CR rate of 27%. In a retrospective analysis of 77 cases of ENKTL, Li et al. found that anthracycline- containing chemotherapy (CT) alone resulted in worse response compared with radiation (RT) plus CT( CR, 50% vs. 74%; 5-year OS, 15% vs. 59%). There was also high incidence of locoregional and systemic failure (45% and 61%, respectively). In our study, interim assessment after 4 cycles of CHOP-L without RT demonstrated a CR rate of 71.5% (27/38). Therefore CHOP-L alone achieved high rate of disease-control comparable to CCRT (Table 5). This finding is very important in comparison to CCRT because CCRT frequently caused serious mucosal toxicity, severe myelosuppression which led to delay of chemotherapy schedule.
Hypersensitivity reactions to L-asparaginase occurred in up to 30% of patients. Recently, several studies confirmed that PEG-asparaginase had similar efficacy to L-asparaginase in childhood acute lymphoblastic leukemia[35, 36]. In this study, 28.9% (11/38) of patients experienced an allergic reaction which happened after a median of 2 cycles of L-asparaginase chemotherapy (range 1–5 cycles). PEG-asparaginase was used in a total of 28 cycles, which accounted for 14.5% of all CHOP-L cycles, and the median cycles were 2 (range, 1-5 cycles). From statistically analysis, using PEG-asparaginase did not affect the CR rate, PFS, DFS and OS. PEG-asparaginase may become another good selection in the management of ENKTL. A multicenter prospective study is underway using PEG-asparaginase containing regimen in the treatment of newly diagnosed ENKTL in China.
Age, B symptoms, ECOG score, regional lymph node involvement, local tumor invasion, clinical stage, CR rate, lymphopenia, IPI and NK/T-cell PI were reported to have prognostic significance in ENKTL and T cell lymphoma[37, 38]. In this study, univariate analysis showed that Ann Arbor stage, B symptoms, ECOG score, IPI score, NK/T-cell PI score, LDH (>240 IU/L), leukopenia (<4.0 × 109/L) and CR were independent factors for OS and PFS in ENKTL. Leukopenia is frequently seen in ENKTL patients, and may cause delay of chemotherapy. In this study, leukopenia occurred in 23.7% (9/38) of patients who had no bone marrow involvement, and appeared to be associated with inferior survival. But regional lymph node involvement, tumor extending to adjacent organ/tissue in UNKTL and bony invasion or perforation did not affect the survival, possibly due to the high efficacy of L-asparaginase.
There were frequent grade 3 to 4 hematologic toxicities (76.3% for leukopenia and 84.2% for neutropenia) in this study, much higher than our previous study using L-asparaginase, vincristine plus dexamethasone in relapsed or refractory cases, in which 2.2% of cases experienced grade 3 to 4 leukopenia. Myelosuppression, nausea or vomiting, and liver dysfunction were more frequent than those in CHOP-21 regimen used in aggressive lymphoma[39, 40], but much less than those occurring in SMILE study. There was no treatment-related death in this study.
In conclusion, this prospective phase II study demonstrated that CHOP-L in combination with radiotherapy is a highly effective and well-tolerated treatment for patients with newly- diagnosed ENKTL.
This study was supported by Beijing Municipal Science & Technology Commission No.Z111107058811020.
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute
Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007, 139 (4): 532-544. 10.1111/j.1365-2141.2007.06835.x.View ArticlePubMed
Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C: Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012, 138 (3): 429-434. 10.1309/AJCP7YLTQPUSDQ5C.View ArticlePubMed
Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J: Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008, 80 (1): 55-60.PubMed
Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK: Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000, 18 (1): 54-63.PubMed
Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006, 24 (1): 181-189. 10.1200/JCO.2005.03.2573.View ArticlePubMed
Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, Yoon JH, Kim GE: Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004, 59 (4): 1127-1137. 10.1016/j.ijrobp.2003.12.006.View ArticlePubMed
Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H: Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006, 106 (3): 609-615. 10.1002/cncr.21656.View ArticlePubMed
Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J: L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009, 88 (7): 647-652. 10.1007/s00277-008-0669-3.View ArticlePubMed
Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thieblemont C: L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009, 20 (1): 110-116.View ArticlePubMed
Obama K, Tara M, Niina K: L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol. 2003, 78 (3): 248-250. 10.1007/BF02983802.View ArticlePubMed
Yong W, Zhang Y, Zheng W: The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2000, 21 (11): 577-579.PubMed
Yong W, Zheng W, Zhang Y: Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma. Zhonghua Yi Xue Za Zhi. 2001, 81 (13): 773-775.PubMed
Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J: L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003, 78 (2): 163-167. 10.1007/BF02983387.View ArticlePubMed
Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J: Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006, 24 (1): 28-32. 10.1002/hon.765.View ArticlePubMed
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011, 117 (6): 1834-1839. 10.1182/blood-2010-09-307454.View ArticlePubMed
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29 (33): 4410-4416. 10.1200/JCO.2011.35.6287.View ArticlePubMed
Jaccard A, Hermine O: Extranodal natural killer/T-cell lymphoma: advances in the management. Curr Opin Oncol. 2011, 23 (5): 429-435. 10.1097/CCO.0b013e328349aba6.View ArticlePubMed
Yamaguchi M: Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol. 2012, 96 (5): 562-571. 10.1007/s12185-012-1189-4.View ArticlePubMed
Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, Junker R: Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003, 101 (7): 2529-2533. 10.1182/blood-2002-06-1901.View ArticlePubMed
Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC: Extranodal NK/T- cell lymphoma, nasal type. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon, France: IARC PRESS, 285-288. 4
Kim TM, Heo DS: Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009, 100 (12): 2242-2248. 10.1111/j.1349-7006.2009.01319.x.View ArticlePubMed
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH: Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005, 41 (10): 1402-1408. 10.1016/j.ejca.2005.03.010.View ArticlePubMed
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS: Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24 (4): 612-618. 10.1200/JCO.2005.04.1384.View ArticlePubMed
Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009, 27 (35): 6027-6032. 10.1200/JCO.2009.23.8592.View ArticlePubMed
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009, 27 (33): 5594-5600. 10.1200/JCO.2009.23.8295.View ArticlePubMed
Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH, Moon SR, Lee HS, Choi EC, Kim KM: Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001, 61 (3): 261-269. 10.1016/S0167-8140(01)00428-5.View ArticlePubMed
Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009, 113 (17): 3931-3937. 10.1182/blood-2008-10-185256.View ArticlePubMed
Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL: Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004, 100 (2): 366-375. 10.1002/cncr.11908.View ArticlePubMed
Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS: SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012, 120 (15): 2973-2980. 10.1182/blood-2012-05-431460.View ArticlePubMed
Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD: Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010, 115 (7): 1351-1353. 10.1182/blood-2009-09-245951.PubMed CentralView ArticlePubMed
Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002, 99 (6): 1986-1994. 10.1182/blood.V99.6.1986.View ArticlePubMed
The Cooperation Group of Phase II Clinical Trial of PEG-Asp: Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2008, 29 (1): 29-33.
Chauchet A, Michallet A-S, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T: Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol. 2012, 5 (1): 27-10.1186/1756-8722-5-27.PubMed CentralView ArticlePubMed
Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011, 4 (1): 34-10.1186/1756-8722-4-34.PubMed CentralView ArticlePubMed
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004, 104 (3): 626-633. 10.1182/blood-2003-06-2094.View ArticlePubMed
Jin X, Ding H, Ding N, Fu Z, Song Y, Zhu J: Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. J Hematol Oncol. 2012, 5 (1): 51-10.1186/1756-8722-5-51.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.